Eli Lilly and Company (NYSE: LLY) announced positive topline results from the QWINT-2 and QWINT-4 phase 3 clinical trials for once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes. These trials included both insulin-naïve patients and those requiring…
SunLink Health Systems, Inc. (NYSE American: SSY) disclosed today a loss from continuing operations of $824,000 (equating to a loss of $0.12 per fully diluted share) for its third fiscal quarter concluding on March 31, 2024. This contrasts with a…
OmniAb has announced its participation in the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit, held at the Omni Hotel. Earlier today, the company presented an overview of xPloration, a high-throughput single B-cell screening platform enhanced…
Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders such as complement-mediated diseases, cancers, and addictive and compulsive disorders, has reported…
VBI Vaccines Inc. (Nasdaq: VBIV) Announces Q1 2024 Business Update and Financial Results VBI Vaccines Inc. (Nasdaq: VBIV), a biopharmaceutical company focused on immunology to develop potent disease prevention and treatment solutions, today released a business update and financial results…
Incyte Corporation (Nasdaq:INCY) announced today that its Board of Directors has greenlit a $2.0 billion share repurchase program. As part of this initiative, the company has initiated a modified “Dutch Auction” tender offer, aiming to buy back shares of its…
Eisai announced today that it has received approval in China for an additional indication of its antiepileptic drug (AED) Fycompa® (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures in patients aged 12 years and older. Fycompa…
Novo Nordisk announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a study involving 254 participants over 26 weeks. This open-label, randomized, controlled, multi-arm trial assessed the efficacy and safety of once-weekly and once-monthly subcutaneous Mim8 compared…
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) disclosed today that its Compensation Committee, a part of Mirum’s Board of Directors, has authorized the allocation of inducement awards to 11 new recruits under the company’s 2020 Inducement Plan. These awards encompass non-qualified stock…
The U.S. Food and Drug Administration (U.S. FDA) has granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY® (epcoritamab-bysp) aimed at treating adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of…
Summary of Financial Highlights: In the first quarter of 2024, the company experienced significant growth across various metrics: Overall, the company demonstrated robust growth in revenues and product sales, despite challenges such as increased operating expenses and a shift in…
Novartis to Acquire Mariana Oncology, Enhancing Radioligand Therapy Portfolio Novartis has announced its agreement to acquire Mariana Oncology, a biotechnology company headquartered in Watertown, Massachusetts, specializing in the development of innovative radioligand therapies (RLTs) for cancers with significant unmet medical…